Jeffrey V. Poulton, EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 2,254 shares at $244.41 ($549K) on 2025-03-03, disclosed to the SEC on 2025-03-05.
Open-market sale of $549k ALNY by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $242.37 | 350 | $85K | 15.5% |
| 2 | $242.37 | 350 | $85K | 15.5% |
| 3 | $243.36 | 382 | $93K | 16.9% |
| 4 | $243.36 | 382 | $93K | 16.9% |
| 5 | $244.41 | 258 | $63K | 11.5% |
| 6 | $244.41 | 258 |
| $63K |
| 11.5% |
| 7 | $245.26 | 189 | $46K | 8.4% |
| 8 | $246.18 | 77 | $19K | 3.5% |
| 9 | $247.35 | 7 | $2K | 0.3% |
| 10 | $248.36 | 1 | $248 | 0.0% |
| Total | $243.56 avg | 2,254 | $549K | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.0M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $3.4M | — | Filing → |